SimpleScreen™ achieved 85% sensitivity for CRC and 22% for advanced precancerous lesions at 90% specificity. Performance improvements are due to optimized assay reagents, automated workflows, and a ...
Your source for the latest in AI Native Development — news, insights, and real-world developer experiences. Your source for the latest in AI Native Development — news, insights, and real-world ...
Non-animal framework based on new approach methodologies (NAMs) for chemical hazard identification and risk assessment. The framework comprises three modules: (1) high-throughput screening to address ...
The FDA has granted Cleveland Diagnostics’ IsoPSA test premarket approval (PMA) to help detect prostate cancer in men aged 50 years or older with elevated PSA levels. IsoPSA is a blood assay that ...
Gov. Maura Healey unveiled proposals for a new high school graduation framework, more than a year after voters decided to repeal the MCAS graduation requirement. Students would be required to take, ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a ...
The headline reads, “Breakthrough blood test finally confirms Chronic Fatigue Syndrome.” As you might imagine, the story is far more complicated than that. Let’s start with some background of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results